Biomarcadores de respuesta inmune celular asociados con enfermedades crónicas no transmisibles

datacite.rightshttp://purl.org/coar/access_right/c_16eceng
dc.contributor.advisorPeña Merlano, Engelbert
dc.contributor.authorAcosta Redondo, Luz Dayana
dc.contributor.authorGuzman Padilla, Alvaro Yesid
dc.contributor.authorPadilla Ojeda, Kenneth David
dc.date.accessioned2021-07-12T14:06:29Z
dc.date.available2021-07-12T14:06:29Z
dc.date.issued2020-06
dc.description.abstractLa respuesta adaptativa celular tiene como propósito fundamental la generación y liberación de Citocinas, moléculas de naturaleza proteica o glicoproteica que cumplen diversidad de funciones y son potencializadoras de todas las respuestas inmunes, siendo mayormente producidas por Linfocitos TCD4+ de todas las subpoblaciones, resultando más determinantes las generadas por los Th1 y Th2. Las citocinas actúan fundamentalmente como reguladores de las respuestas inmunitaria e inflamatoria. Esta respuesta resulta determinante en un sinnúmero de eventos y complicaciones, no siendo ajenas las enfermedades crónicas no trasmisibles. En el presente trabajo se pretende establecer el patrón de respuesta inmune adaptativa mediante el estudio de los niveles de interleucinas Th1 y Th2 en pacientes con enfermedades crónicas no transmisibles (ECNT) como Hipertensión Arterial (HTA), Diabetes Mellitus tipo 2 (DM2) y Cáncer para establecer la asociación de estas como Bio-marcadores de respuesta adaptativa celular y propender por la reducción de los índices de morbilidad y mortalidad en los individuos afectados.spa
dc.description.abstractThe cellular adaptive response has as its fundamental purpose the generation and release of Cytokines, molecules of a protein or glycoprotein nature that fulfill a variety of functions and are potentiators of all immune responses, being mainly produced by TCD4 lymphocytes from all subpopulations, the generated by Th1 and Th2. Cytokines primarily act as regulators of immune and inflammatory responses. This response is decisive in countless events and complications, and non-communicable chronic diseases are not foreign. The present work aims to establish the adaptive immune response pattern by studying the levels of Th1 and Th2 interleukins in patients with chronic noncommunicable diseases such as Arterial Hypertension (AHT), Diabetes Mellitus type 2 (DM2) and Cancer in the city. from Barranquilla, Colombia during the period 2019 - 2020, to establish the association of these as Bio-markers of cellular adaptive response and promote the reduction of morbidity and mortality rates in affected individuals.eng
dc.format.mimetypepdfspa
dc.identifier.urihttps://hdl.handle.net/20.500.12442/7972
dc.language.isospaspa
dc.publisherEdiciones Universidad Simón Bolívarspa
dc.publisherFacultad de Ciencias de la Saludspa
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional
dc.rights.accessrightsinfo:eu-repo/semantics/restrictedAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectLinfocitosspa
dc.subjectCitocinasspa
dc.subjectCáncerspa
dc.subjectBiomarcadoresspa
dc.subjectDiabetes tipo 2spa
dc.titleBiomarcadores de respuesta inmune celular asociados con enfermedades crónicas no transmisiblesspa
dc.type.driverinfo:eu-repo/semantics/bachelorThesiseng
dc.type.spaTrabajo de grado - pregradospa
dcterms.referencesOzawa K, Miyazaki M, Natsuhisa M, Takano K, Nakatani Y, Hatzaki M, et al. The endoplasmic reticulum chaperone improves insulin resistance in type 2 diabetes. Diabetes 2005;54:657-663.eng
dcterms.referencesLin Y, Chen Y, Cline GW, Zhang D, Zong H, Wang Y, et al. The hyperglycemia-induced inflammatory response in adipocytes: the role of reactive oxygen species. J Biol Chem 2005;280:4617-4626.eng
dcterms.referencesLowell BB, Shulman GI. Mitochondrial dysfunction and type 2 diabetes. Science 2005;307:384-387eng
dcterms.referencesWoo SR, Corrales L, Gajewski TF. Innate immune recognition of cancer. Annu Rev Immunol. 2015; 33: 445-474.eng
dcterms.referencesYanan L, Gang Z. Cancer and innate immune system interactions: translational potentials for cáncer immunotherapy. J Immunother. 2012; 35 (4): 299-308.eng
dcterms.referencesGrivennikov SI, Greten FR, Karin M. Immunity, infl ammation and cancer. Cell. 2010; 140 (6): 883-899.eng
dcterms.referencesMedzhitov R. Origin and physiological roles of infl ammation. Nature. 2008; 454 (7203): 428-435eng
dcterms.referencesCALHOUN, DA., BAKIR, SE. and OPARIL, S. (2003). Etiology and pathogenesis of essential hypertension. En: Crawford, MH and DiMarco, JP (eds). Cardiology (p.3.1 – 3.10). London: Mosby International.eng
dcterms.referencesWeber, MJ. (2003). Natural history of hypertension. J Hypertension. 21(6): S37 – S46.eng
dcterms.referencesSavoia, C. and Schiffrin, EL. (2006). Inflammation in hypertension. Curr Opin Nephrol Hypertens. 15: 152 – 158.eng
dcterms.referencesHarrison, DG., Marvar, PJ., and Titze, JM. (2012). Vascular inflammatory cells in hypertension. Vasc Physiology. 128(3): 1 – 8.eng
dcterms.referencesLibby, P., Simon, Di, and Rogers, C. (2003). Inflammation and arterial injury. En: Topol EJ (ed). Interventional cardiology (p. 381 – 389). Philadelphia: Elsevier Science.eng
dcterms.referencesAndroulakis, ES., Tousoulis, D., Papageorgiou, N., Tsioufis, C., Kallikazaros, I. and Stefanadis, C. (2009). Review Article Essential Hypertension: Is There a Role for Inflammatory Mechanisms? Cardiology in Review. 17: 216 – 221.eng
dcterms.referencesSriramula, S., Haque, M., Majid, DSA. and Francis, J. (2008). Involvement of tumor necrosis factor-alfa in angiotensin II-mediated effects on salt appetite, hypertension, andcardiac hypertrophy. Hypertension. 51: 1345 – 1351.eng
dcterms.referencesSerrano, M., Morte, S., Álvarez, V., Zugarramurdi, P. y Palacios, M. (2001). El proceso inflamatorio de la enfermedad cardiovascular: nuevos marcadores. An Sist Sanit Navar. 24: 315 – 32.spa
dcterms.referencesPearson, TA., Mensah, GA., Alexander, RW., Anderson, JL., Cannon, RO., Criqui, M., et al. (2003). Markers of inflammation and Cardiovascular Disease. Application to Clinical and Public Health Practice. A Statement for Healthcare Professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 107: 499 – 511.eng
dcterms.referencesFiorentino, DF., Bond, MW. and Mosmann, TR. (1989). Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med. 170: 2081 – 95.eng
dcterms.referencesMallat, Z., Heymes, C., Ohan, J., Faggin, E., Leseche, G. and Tedgui, A. (1999). Expression of interleukin-10 in advanced human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 19: 611 – 6.eng
dcterms.referencesPérez-Fernández, R. y Kaski, JC. (2002). Interleucina-10 y enfermedad coronaria. Rev Esp Cardiol. 55: 738 – 50.spa
dcterms.referencesNishii, M., Inomata, T., Takehana, H., Takeuchi, I., Nakano, H., Koitabashi, T., et al. (2004). Serum levels of interleukin-10 on admission as a prognostic predictor of human fulminant myocarditis. J Am Coll Cardiol. 44: 1292 – 7.eng
dcterms.referencesKnowlton, KU. and Yajima, T. (2004). Interleukin-10: biomarker of pathologic cytokine in fulminant myocarditis?. J Am Coll Cardiol. 44: 1298 – 300. 22. Du Clos, TW. (1989). C-reactive protein reacts with the U1 small nuclear ribonucleoprotein. J. Immunol. 143: 2553 – 2559.eng
dcterms.referencesYeh, ETH. and Willerson, JT. (2003). Coming of age of C reactive protein. Using inflammation markers in cardiology. Circulation. 107: 370 – 372.eng
dcterms.referencesRidker, PM. (2003). Clinical application of C Reactive Protein for cardiovascular disease detection and prevention. Circulation. 107: 363 – 369.eng
dcterms.referencesStumpe, KO., Agabiti Rosei, E. and Scholze J. (2007). Carotid atherosclerosis regression by angiotensin receptor blockade: Results of the Multicenter Olmesartan Atherosclerosis Regression Evaluation (MORE) study. J Clin Hypertens. 9(5): A42.eng
dcterms.referencesFirestein, Gary S., MD; Budd, Ralph C., MD; Gabriel, Sherine E., MD, MSc; McInnes, Iain B., PhD, FRCP, FRSE, FMedSci; O'Dell, James R., MD. Kelley y Firestein. Tratado de reumatología. España :; 2018eng
dcterms.referencesOle P. Kristiansen12 y Thomas Mandrup -Pulsión. Interleucina-6 y Diabete. http://diabetes.diabetesjournals.org/content/54/suppl_2/S114.eng
dcterms.referencesL. Díaz Naya y E. Delgado Álvarez. Diabetes mellitus Criterios de diagnóstico y clasificación. Epidemiología.Etiopatogenia. Evaluación inicial del paciente con diabetes. Medicina - Programa de Formación Médica Continuada Acreditado 2016spa
dcterms.referencesS. Aznar Rodríguez, A. Lomas Meneses, RP Quílez Toboso y I. Huguet Moreno. Diabetes mellitus Endocrinología, Diabetes y Nutrición 2012; Volumen 11 2017spa
dcterms.referencesIgnacio Conget a. Diagnóstico, clasificación y patogenia de la diabetes mellitus. Revista Española De Cardiologia 200; Vol. 55. (Núm. 05.) ).2018spa
dcterms.referencesV. Rigalleau, B. Cherifi, L. Blanco, L. Alexandre y K. Mohammedi. Tratamiento de la diabetes tipo 2. Tratado de medicina 2018; Volumen 22 2016spa
oaire.versioninfo:eu-repo/semantics/acceptedVersioneng
sb.programaMedicinaspa
sb.sedeSede Barranquillaspa

Archivos